We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App





Oxford University to Study Wonder Drug Ivermectin as Possible Treatment for COVID-19

By HospiMedica International staff writers
Posted on 28 Jun 2021
Print article
Illustration
Illustration
A new trial led by the University of Oxford (Oxford, UK) will investigate a widely used anti-parasitic drug, ivermectin as a possible treatment for COVID-19.

Ivermectin is being investigated in the UK as part of the Platform Randomized Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings. PRINCIPLE is investigating treatments for people at more risk of serious illness from COVID-19 which can speed up recovery, reduce the severity of symptoms and prevent the need for hospital admission. The study has so far recruited more than 5,000 volunteers from across the UK.

Ivermectin is a safe, broad spectrum anti-parasitic drug which is in wide use globally to treat parasitic infections. With known antiviral properties, ivermectin has been shown to reduce SARS-CoV-2 replication in laboratory studies. Small pilot studies show that early administration with ivermectin can reduce viral load and the duration of symptoms in some patients with mild COVID-19. Even though ivermectin is used routinely in some countries to treat COVID-19, there is little evidence from large-scale randomized controlled trials to demonstrate that it can speed up recovery from the illness or reduce hospital admission.

Ivermectin is the seventh treatment to be investigated in the PRINCIPLE trial, and is currently being evaluated alongside the influenza antiviral favipiravir. Following a screening questionnaire to confirm eligibility, participants enrolled in the study will be randomly assigned to receive a three-day course of ivermectin treatment. They will be followed-up for 28 days and will be compared with participants who have been assigned to receive the usual standard of NHS care only. People aged 18 to 64 with certain underlying health conditions or shortness of breath from COVID-19, or aged over 65, are eligible to join the trial within the first 14 days of experiencing COVID-19 symptoms or receiving a positive test.

“Ivermectin is readily available globally, has been in wide use for many other infectious conditions so it’s a well-known medicine with a good safety profile, and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries,” said Professor Chris Butler, from the University Oxford’s Nuffield Department of Primary Care Health Sciences, Joint Chief Investigator of the PRINCIPLE trial. “By including ivermectin in a large-scale trial like PRINCIPLE, we hope to generate robust evidence to determine how effective the treatment is against COVID-19, and whether there are benefits or harms associated with its use.”

Related Links:
University of Oxford


Print article

Channels

Business

view channel
Image: BD Seeks to Transform Patient Experience Through Vision of `One-Stick Hospital Stay` (Photo courtesy of BD)

BD Seeks to Transform Patient Experience Through Vision of 'One-Stick Hospital Stay'

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.